An initial safety study of Gedatolisib plus PTK7-ADC for metastatic triple-negative breast cancer
Phase 1 study to evaluate the safety and effect of Gedatolisib and PTK7-ADC for the treatment of triple negative breast cancer.
The purpose of this study is to evaluate the safety of Gedatolisib plus PTK7-ADC in patients with metastatic triple-negative or estrogen poor breast cancer as assessed by NCI CTC v4.0 criteria.
- IRB Number: 1704239900 (IUSCC-0613)
- Research Study Identifier: TX7919
- Principal Investigator: Kathy Miller, MD
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required